Nothing Special   »   [go: up one dir, main page]

SG11201703880VA - Triazolopyrimidine compounds and uses thereof - Google Patents

Triazolopyrimidine compounds and uses thereof

Info

Publication number
SG11201703880VA
SG11201703880VA SG11201703880VA SG11201703880VA SG11201703880VA SG 11201703880V A SG11201703880V A SG 11201703880VA SG 11201703880V A SG11201703880V A SG 11201703880VA SG 11201703880V A SG11201703880V A SG 11201703880VA SG 11201703880V A SG11201703880V A SG 11201703880VA
Authority
SG
Singapore
Prior art keywords
triazolopyrimidine compounds
triazolopyrimidine
compounds
Prior art date
Application number
SG11201703880VA
Other languages
English (en)
Inventor
Ho Man Chan
Xiang-Ju Justin Gu
Ying Huang
Ling Li
Yuan Mi
Wei Qi
Martin Sendzik
Long Wang
Zhengtian Yu
Hailong Zhang
Ji Yue Zhang (Jeff)
Man Zhang
Qiong Zhang
Kehao Zhao
Yongfeng Sun
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201703880VA publication Critical patent/SG11201703880VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201703880VA 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof SG11201703880VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23
PCT/IB2015/059843 WO2016103155A1 (en) 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof

Publications (1)

Publication Number Publication Date
SG11201703880VA true SG11201703880VA (en) 2017-07-28

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703880VA SG11201703880VA (en) 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof

Country Status (40)

Country Link
US (5) US9580437B2 (hu)
EP (1) EP3237418B1 (hu)
JP (1) JP6736559B2 (hu)
KR (1) KR102534028B1 (hu)
CN (1) CN107108637B (hu)
AU (1) AU2015370524B2 (hu)
BR (1) BR112017010354B8 (hu)
CA (1) CA2969090C (hu)
CL (1) CL2017001572A1 (hu)
CO (1) CO2017005992A2 (hu)
CR (1) CR20170285A (hu)
CY (1) CY1121901T1 (hu)
DK (1) DK3237418T3 (hu)
DO (1) DOP2017000149A (hu)
EA (1) EA032416B1 (hu)
EC (1) ECSP17047153A (hu)
ES (1) ES2722048T3 (hu)
GT (1) GT201700146A (hu)
HR (1) HRP20190805T1 (hu)
HU (1) HUE043060T2 (hu)
IL (1) IL252135B (hu)
JO (1) JO3489B1 (hu)
LT (1) LT3237418T (hu)
ME (1) ME03385B (hu)
MX (1) MX2017008529A (hu)
MY (1) MY186837A (hu)
NZ (1) NZ731664A (hu)
PE (1) PE20171307A1 (hu)
PH (1) PH12017501016A1 (hu)
PL (1) PL3237418T3 (hu)
PT (1) PT3237418T (hu)
RS (1) RS58679B1 (hu)
SG (1) SG11201703880VA (hu)
SI (1) SI3237418T1 (hu)
SV (1) SV2017005472A (hu)
TN (1) TN2017000204A1 (hu)
TW (1) TWI694076B (hu)
UA (1) UA120945C2 (hu)
UY (1) UY36462A (hu)
WO (1) WO2016103155A1 (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY186837A (en) * 2014-12-23 2021-08-25 Novartis Ag Triazolopyrimidine compounds and uses thereof
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN109790166A (zh) 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of triazolopyrimidine compound
WO2017221092A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
KR20230156174A (ko) 2016-07-12 2023-11-13 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
TWI820013B (zh) 2017-01-23 2023-11-01 美商銳新醫藥公司 作為別構ｓｈｐ２抑制劑之雙環化合物
EP4230623A3 (en) 2017-01-23 2023-10-11 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
BR112019017108A2 (pt) * 2017-03-16 2020-04-07 Jiangsu Hengrui Medicine Co derivados de heteroaril[4,3-c]pirimidina-5-amina, método de preparação dos mesmos, e usos médicos dos mesmos
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
EP3724189B1 (en) * 2017-12-15 2023-10-04 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
US11591312B2 (en) 2018-01-23 2023-02-28 Basf Se Halogenation of pyridine derivatives
PT4043466T (pt) * 2018-01-31 2024-10-14 Mirati Therapeutics Inc Inibidores de prc2
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
EP3889153A4 (en) * 2018-11-30 2022-09-07 Tuojie Biotech (Shanghai) Co., Ltd. PYRIMIDINE AND PENTAGONAL HETEROCYCLE DERIVATIVE OF NITROGEN, METHOD FOR THE PREPARATION AND MEDICAL APPLICATIONS
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
SG11202110092PA (en) 2019-03-15 2021-10-28 Fulcrum Therapeutics Inc Macrocyclic azolopyridine derivatives as eed and prc2 modulators
JP7299307B2 (ja) * 2019-04-03 2023-06-27 テラ・ストーン株式会社 チミン核酸塩基をベースとするトリアゾロピリミジン類及びその製造方法
EP3959214A1 (en) 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
US11814734B2 (en) 2019-05-13 2023-11-14 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
JP2022535267A (ja) * 2019-06-05 2022-08-05 アセネックス インコーポレイテッド 乾癬を治療および／または予防する方法
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
PH12021553233A1 (en) 2019-07-16 2022-09-19 Univ Michigan Regents Imidazopyrimidines as eed inhibitors and the use thereof
PH12022550441A1 (en) * 2019-08-22 2022-12-19 Blueray Therapeutics Shanghai Co Ltd Azaheteroaryl compound and application thereof
EP4034535A4 (en) * 2019-09-26 2023-11-22 Novartis AG AZACHINOLINE COMPOUNDS AND USES THEREOF
CA3156546A1 (en) * 2019-11-01 2021-05-06 Wei Qi Substituted [1,2,4]triazolo-[4,3-c]pyrimidine compounds and use thereof as eed inhibitors
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
CN113636993B (zh) * 2020-05-11 2022-08-19 苏州亚盛药业有限公司 (5-氟-2,3-二氢苯并呋喃-4-基)甲胺或其盐的制备方法及其中间体
CN115916209A (zh) 2020-05-28 2023-04-04 诺华股份有限公司 用于治疗PRC2介导的疾病或障碍的N-((5-氟-2,3-二氢苯并呋喃-4-基)甲基)-8-(2-甲基吡啶-3-基)-[1,2,4]三唑并[4,3-c]嘧啶-5-胺或其药学上可接受的盐的给药方案
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023016511A1 (zh) * 2021-08-11 2023-02-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
SE519662C2 (sv) * 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
WO2003034997A2 (en) * 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BRPI0308113B8 (pt) 2002-03-08 2021-05-25 Eisai Co Ltd compostos macrocíclicos úteis como substâncias farmacêuticas
CN101486682B (zh) 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) * 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
WO2005118796A2 (en) 2004-06-01 2005-12-15 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
DK1912636T3 (da) 2005-07-21 2014-07-21 Ardea Biosciences Inc N-(arylamino)-sulfonamid-inhibitorer af mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2041575A2 (en) 2006-03-31 2009-04-01 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
CA2673784A1 (en) 2006-12-27 2008-07-10 Usc Stevens-University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
ES2537352T3 (es) 2007-09-12 2015-06-05 Genentech, Inc. Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso
CA2701292C (en) 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010111712A2 (en) 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
LT2566327T (lt) * 2010-05-07 2017-05-25 Glaxosmithkline Llc Indolai
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
US20140213475A1 (en) 2011-07-14 2014-07-31 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
WO2013049770A2 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
EP2825161B1 (en) 2012-03-12 2019-01-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
CN105189506A (zh) 2012-11-19 2015-12-23 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
ME02730B (me) 2013-02-11 2017-10-20 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba
WO2014153030A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2970306A4 (en) * 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
US10167286B2 (en) 2014-02-11 2019-01-01 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
BR112017009784B1 (pt) 2014-11-14 2021-12-28 Basf Se Usos de um composto, misturas agroquímicas, método para reduzir a nitrificação e método para tratar um fertilizante
PT3033944T (pt) 2014-12-16 2018-05-14 Omya Int Ag Carbonato de cálcio para proteção de plantas
MY186837A (en) * 2014-12-23 2021-08-25 Novartis Ag Triazolopyrimidine compounds and uses thereof
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences

Also Published As

Publication number Publication date
US10220036B2 (en) 2019-03-05
PH12017501016B1 (en) 2017-12-11
IL252135B (en) 2020-06-30
EP3237418A1 (en) 2017-11-01
DK3237418T3 (da) 2019-05-13
CN107108637B (zh) 2019-10-29
US9580437B2 (en) 2017-02-28
EA032416B1 (ru) 2019-05-31
BR112017010354B8 (pt) 2022-10-18
IL252135A0 (en) 2017-07-31
JO3489B1 (ar) 2020-07-05
ECSP17047153A (es) 2019-02-28
KR20170095882A (ko) 2017-08-23
EA201791420A1 (ru) 2017-10-31
UY36462A (es) 2016-07-29
PH12017501016A1 (en) 2017-12-11
US20200323859A1 (en) 2020-10-15
JP2018500342A (ja) 2018-01-11
CN107108637A (zh) 2017-08-29
US11207325B2 (en) 2021-12-28
CA2969090A1 (en) 2016-06-30
CL2017001572A1 (es) 2018-01-12
ES2722048T3 (es) 2019-08-07
EP3237418B1 (en) 2019-01-30
NZ731664A (en) 2024-02-23
US20170348312A1 (en) 2017-12-07
HRP20190805T1 (hr) 2019-06-28
UA120945C2 (uk) 2020-03-10
US11931363B2 (en) 2024-03-19
MY186837A (en) 2021-08-25
AU2015370524A1 (en) 2017-06-01
GT201700146A (es) 2019-06-12
PE20171307A1 (es) 2017-09-05
CO2017005992A2 (es) 2017-10-20
TW201629065A (zh) 2016-08-16
AU2015370524B2 (en) 2018-11-01
CA2969090C (en) 2023-05-02
SI3237418T1 (sl) 2019-06-28
DOP2017000149A (es) 2017-07-15
TN2017000204A1 (en) 2018-10-19
US20230033320A1 (en) 2023-02-02
MX2017008529A (es) 2017-10-25
BR112017010354A2 (pt) 2017-12-26
KR102534028B1 (ko) 2023-05-19
BR112017010354B1 (pt) 2022-09-20
JP6736559B2 (ja) 2020-08-05
LT3237418T (lt) 2019-05-10
CR20170285A (es) 2017-08-21
CY1121901T1 (el) 2020-10-14
RS58679B1 (sr) 2019-06-28
SV2017005472A (es) 2018-06-12
PT3237418T (pt) 2019-05-23
ME03385B (me) 2020-01-20
HUE043060T2 (hu) 2019-07-29
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
US20160176882A1 (en) 2016-06-23
PL3237418T3 (pl) 2019-07-31
WO2016103155A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
IL252135B (en) Triazolopyrimidine compounds and their uses
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
HUE066468T2 (hu) Idegnyugtató norketamin vegyületek és eljárások
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
GB2540892B (en) Pyrrolobenzodiazepine compounds
ZA201701312B (en) Novel imidazopyridazine compounds and their use
HK1243342A1 (zh) 化合物和方法
GB201408091D0 (en) Methods and uses
GB2543375B (en) Compounds and their uses
GB201404301D0 (en) Compounds and combinations
GB201407599D0 (en) New compounds and uses
GB201407596D0 (en) New compounds and uses
GB201402467D0 (en) New Compounds and uses
GB201413411D0 (en) Novel compounds and their use
GB201415788D0 (en) Objects With Multi-Connectivity